Bellevue Group Ag Catalent, Inc. Transaction History

Bellevue Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$72.36 - $113.1 $34,226 - $53,496	473 New	473 $34,000
Q1 2022 May 13, 2022	SELL	$94.19 - $124.49 $2.18 Million - $2.88 Million	-23,100 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$119.57 - $139.07 $1.54 Million - $1.79 Million	-12,900 Reduced 35.83%	23,100 $2.96 Million
Q3 2021 Nov 12, 2021	BUY	$109.17 - $142.35 $3.64 Million - $4.74 Million	33,300 Added 1233.33%	36,000 $4.79 Million
Q1 2021 May 12, 2021	SELL	$101.51 - $125.27 $203,020 - $250,540	-2,000 Reduced 42.55%	2,700 $284,000
Q4 2020 Feb 16, 2021	SELL	$85.88 - $105.36 $85,880 - $105,360	-1,000 Reduced 17.54%	4,700 $489,000
Q2 2020 Aug 13, 2020	SELL	$48.02 - $79.04 $1.99 Million - $3.27 Million	-41,400 Reduced 87.9%	5,700 $418,000
Q1 2020 May 14, 2020	BUY	$36.95 - $62.95 $472,960 - $805,760	12,800 Added 37.32%	47,100 $2.45 Million
Q4 2019 Feb 14, 2020	SELL	$47.06 - $56.64 $150,592 - $181,248	-3,200 Reduced 8.53%	34,300 $1.93 Million
Q2 2019 Aug 14, 2019	BUY	$39.26 - $54.21 $1.47 Million - $2.03 Million	37,500 New	37,500 $2.03 Million

514

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.